Evidence map›Paper›PMID 38469305›Full record

ArticleFrontiers in immunology2024

Benchmarking glycoform-resolved affinity separation - mass spectrometry assays for studying FcγRIIIa binding.

Christoph Gstöttner, Steffen Lippold, Michaela Hook, Feng Yang, Markus Haberger, Manfred Wuhrer, David Falck, Tilman Schlothauer, Elena Domínguez-Vega

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Christoph GstöttnerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
Steffen LippoldProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Michaela HookPharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany.
Feng YangProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Markus HabergerPharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
David FalckCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
Tilman SchlothauerPharma Research and Early Development, Roche Innovation Center, Munich, Germany.
Elena Domínguez-VegaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
Leiden University Medical Center · NLRoche Pharma AG (Germany) · DERoche (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antibody- FcγRIIIa interaction triggers key immunological responses such as antibody dependent cellular cytotoxicity (ADCC), making it highly important for therapeutic mAbs. Due to the direct glycan-glycan interaction with FcγRIIIa receptor, differences in antibody glycosylation can drastically influence the binding affinity. Understanding the differential binding of mAb glycoforms is a very important, yet challenging task due to the co-existence of multiple glycoforms in a sample. Affinity liquid chromatography (AC) and affinity capillary electrophoresis (ACE) hyphenated with mass spectrometry (MS) can provide glycoform-resolved affinity profiles of proteins based on their differences in either dissociation (AC) or equilibrium (ACE) constants. To cross-validate the affinity ranking provided by these complementary novel approaches, both techniques were benchmarked using the same FcγRIIIa constructs. Both approaches were able to assess the mAb - FcγRIIIa interaction in a glycoform selective manner and showed a clear increase in binding for fully versus hemi-fucosylated mAbs. Also, other features, such as increasing affinity with elevated galactosylation or the binding affinity for high mannose glycoforms were consistent. We further applied these approaches to assess the binding towards the F158 allotype of FcγRIIIa, which was not reported before. The FcγRIIIa F158 allotype showed a very similar profile compared to the V158 receptor with the strongest increase in binding due to afucosylation and only a slight increase in binding with additional galactosylation. Both techniques showed a decrease of the binding affinity for high mannose glycoforms for FcγRIIIa F158 compared to the V158 variant. Overall, both approaches provided very comparable results in line with orthogonal methods proving the capabilities of separation-based affinity approaches to study FcγR binding of antibody glycoforms.

Indexed as

Immunoglobulin GReceptors, IgGAntibodies, MonoclonalMannoseMass SpectrometryPolysaccharidesAntibodies, MonoclonalImmunoglobulin GMannosePolysaccharidesReceptors, IgGaffinity capillary electrophoresisaffinity chromatographyaffinity interactionFcγRIIIA receptorglycosylationmass spectrometrymonoclonal antibody

Identifiers

PMID38469305
PMCPMC10925690
OpenAlexW4392165311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.